Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain

1. Martín García-Sancho, A.
2. Presa, M.
3. Pardo, C.
4. Martín-Escudero, V.
5. Oyagüez, I.
6. Ortiz-Maldonado, V.

Esportatu

Esportatu

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Esportatu

×

Dokumentua ezin da beste atari batetik esportatu.

Testu osoa

lock_openTestu osoa externo

DOI: 10.3390/CANCERS16132301 GOOGLE SCHOLAR lock_openSarbide irekia editor